Skip to main content

Advertisement

Figure 3 | Arthritis Research & Therapy

Figure 3

From: Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Figure 3

Digital images showing complete resolution of tophi in two patients who received pegloticase biweekly. (A) Photograph of patient 1 showing baseline tophus on the medial aspect of the patient’s right third distal interphalangeal (DIP) joint. (B) Photograph of patient 1 showing complete resolution of target tophus at week 13. Note also the reduction in the area of a large tophus on the third proximal interphalangeal joint. (C) Photograph of patient 2 showing baseline tophi on the patient’s right thumb; on the second, third and fourth DIP joints with ulcerations; and on the fifth proximal interphalangeal joint after six months of treatment with placebo in the randomized controlled trials. (D) Photograph of patient 2 showing complete resolution of target tophi on four digits after 25 weeks of treatment with twice-monthly pegloticase in the open-label extension study.

Back to article page